Supplemental Table 3.2 Data extraction sheet for cohort studies

Publication and study details									
Authors									
Year of publication									
Country									
Study design									
Number of participants									
Groups	Group 1 platelet count threshold ($\times 10^9$/L)			Group 2 platelet count threshold ($\times 10^9$/L)			Group N platelet count threshold ($\times 10^9$/L)		

Clinical characteristics									
	Group 1 median (or mean)	Group 1 IQR (or SD)	Group 1 total	Group 2 median (or mean)	Group 2 IQR (or SD)	Group 2 total	Group N median (or mean)	Group N IQR (or SD)	Group N total
GA (w)									
BW (g)									
Platelet count $\times 10^9$/L)									
Number of platelet transfusions									

Primary outcomes						
	Group 1 event	Group 1 total	Group 2 event	Group 2 total	Group N event	Group N total
In-hospital mortality or major bleeding events						

Bleeding episodes						
IVH						
ICH						
PH						
Frank rectal bleeding						
Other bleeding						

Secondary outcomes						
Major morbidity						
	Group 1	Group 1 total	Group 2	Group 2 total	Group N event	Group N total

	event			event					
PDA									
BPD									
Sepsis									
NEC									
ROP									
Other outcome measures									
LOS (days)	Group 1 median (or mean)	Group 1 IQR (or SD)	Group 1 total	Group 2 median (or mean)	Group 2 IQR (or SD)	Group 2 total	Group N median (or mean)	Group N IQR (or SD)	Group N total

Adverse effects of transfusion	Group 1 event	Group 1 total	Group 2 event	Group 2 total	Group N event	Group N total

Other information	
Type and dose of platelet component	
Any sponsorship or funding	

IQR: interquartile range; SD: standard deviation; GA: gestational age; BW: birth weight; IVH: intraventricular haemorrhage; ICH: intracranial haemorrhage; PH: pulmonary haemorrhage; BPD: bronchopulmonary dysplasia; NEC: necrotizing enterocolitis; PDA: patent ductus arteriosus; NEC: necrotizing enterocolitis; ROP: retinopathy of prematurity; LOS: length of stay